CA2436104A1 - Methode d'induction de la reproduction in vitro du virus de l'hepatite c (vhc), cellules et lignees cellulaires permettant la reproduction fidele du vhc et trousse connexe - Google Patents
Methode d'induction de la reproduction in vitro du virus de l'hepatite c (vhc), cellules et lignees cellulaires permettant la reproduction fidele du vhc et trousse connexe Download PDFInfo
- Publication number
- CA2436104A1 CA2436104A1 CA 2436104 CA2436104A CA2436104A1 CA 2436104 A1 CA2436104 A1 CA 2436104A1 CA 2436104 CA2436104 CA 2436104 CA 2436104 A CA2436104 A CA 2436104A CA 2436104 A1 CA2436104 A1 CA 2436104A1
- Authority
- CA
- Canada
- Prior art keywords
- hcv
- replication
- virus
- cells
- yes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000010076 replication Effects 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims abstract description 51
- 238000000338 in vitro Methods 0.000 title claims abstract description 18
- 230000001939 inductive effect Effects 0.000 title claims abstract description 8
- 241000711549 Hepacivirus C Species 0.000 title abstract description 288
- 208000015181 infectious disease Diseases 0.000 claims abstract description 45
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 14
- 238000003556 assay Methods 0.000 claims abstract description 11
- 229960005486 vaccine Drugs 0.000 claims abstract description 10
- 238000011161 development Methods 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 104
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 79
- 241000700605 Viruses Species 0.000 claims description 57
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 20
- 230000003612 virological effect Effects 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 230000004913 activation Effects 0.000 claims description 17
- 230000029812 viral genome replication Effects 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 14
- 210000004443 dendritic cell Anatomy 0.000 claims description 12
- 230000003213 activating effect Effects 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 9
- 230000014616 translation Effects 0.000 claims description 8
- 230000003362 replicative effect Effects 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 210000000265 leukocyte Anatomy 0.000 claims description 6
- 210000001616 monocyte Anatomy 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 239000012190 activator Substances 0.000 claims description 5
- 230000001086 cytosolic effect Effects 0.000 claims description 5
- 239000003226 mitogen Substances 0.000 claims description 5
- 238000007423 screening assay Methods 0.000 claims description 5
- 238000013519 translation Methods 0.000 claims description 5
- 230000032258 transport Effects 0.000 claims description 5
- 230000010415 tropism Effects 0.000 claims description 5
- 230000006656 viral protein synthesis Effects 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 3
- 230000004071 biological effect Effects 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000000099 in vitro assay Methods 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 abstract description 16
- 239000003443 antiviral agent Substances 0.000 abstract description 9
- 238000010200 validation analysis Methods 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000002459 sustained effect Effects 0.000 abstract description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 80
- 108090000623 proteins and genes Proteins 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 32
- 235000018102 proteins Nutrition 0.000 description 31
- 239000002245 particle Substances 0.000 description 27
- 210000003719 b-lymphocyte Anatomy 0.000 description 25
- 101710144111 Non-structural protein 3 Proteins 0.000 description 23
- 239000000284 extract Substances 0.000 description 21
- 239000006228 supernatant Substances 0.000 description 19
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 18
- 238000001514 detection method Methods 0.000 description 17
- 210000001744 T-lymphocyte Anatomy 0.000 description 16
- 238000003753 real-time PCR Methods 0.000 description 16
- 238000003757 reverse transcription PCR Methods 0.000 description 13
- 241000725303 Human immunodeficiency virus Species 0.000 description 12
- 230000000840 anti-viral effect Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 238000010166 immunofluorescence Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 11
- 238000001262 western blot Methods 0.000 description 11
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- 108010047620 Phytohemagglutinins Proteins 0.000 description 10
- 230000001885 phytohemagglutinin Effects 0.000 description 10
- 108010092160 Dactinomycin Proteins 0.000 description 9
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 9
- 108020000999 Viral RNA Proteins 0.000 description 9
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 9
- 229960000640 dactinomycin Drugs 0.000 description 9
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 108010067390 Viral Proteins Proteins 0.000 description 8
- 230000000692 anti-sense effect Effects 0.000 description 8
- 238000003501 co-culture Methods 0.000 description 8
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 230000020411 cell activation Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 101710132601 Capsid protein Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 5
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 5
- 239000000020 Nitrocellulose Substances 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 229920001220 nitrocellulos Polymers 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 4
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 4
- 102100032937 CD40 ligand Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000013381 RNA quantification Methods 0.000 description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 229950004398 broxuridine Drugs 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 229960003920 cocaine Drugs 0.000 description 4
- 238000001493 electron microscopy Methods 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 238000001466 metabolic labeling Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 229960000329 ribavirin Drugs 0.000 description 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 108010029697 CD40 Ligand Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010019799 Hepatitis viral Diseases 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 101710144121 Non-structural protein 5 Proteins 0.000 description 3
- 241000282577 Pan troglodytes Species 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 230000006819 RNA synthesis Effects 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000005188 flotation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 230000007813 immunodeficiency Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229960001797 methadone Drugs 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229940005483 opioid analgesics Drugs 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 201000001862 viral hepatitis Diseases 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241000711557 Hepacivirus Species 0.000 description 2
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 101710125507 Integrase/recombinase Proteins 0.000 description 2
- 239000012741 Laemmli sample buffer Substances 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- -1 SAC Proteins 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000010460 detection of virus Effects 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 244000309457 enveloped RNA virus Species 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 244000052637 human pathogen Species 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 208000007525 plasmablastic lymphoma Diseases 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 230000006807 siRNA silencing Effects 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- NDJNDUULNXNRQD-XKBRQERYSA-N 1-[(2r,4s,5s)-5-[bromo(hydroxy)methyl]-4-hydroxyoxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](C(Br)O)O[C@H]1N1C(=O)NC(=O)C=C1 NDJNDUULNXNRQD-XKBRQERYSA-N 0.000 description 1
- IWFHOSULCAJGRM-UAKXSSHOSA-N 5-bromouridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@@H](O)[C@@H]1N1C(=O)NC(=O)C(Br)=C1 IWFHOSULCAJGRM-UAKXSSHOSA-N 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 101100281953 Homo sapiens GAPDH gene Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 101710159910 Movement protein Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101800003376 Protease-polymerase Proteins 0.000 description 1
- 102100024147 Protein phosphatase 1 regulatory subunit 14A Human genes 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108700010756 Viral Polyproteins Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 108091092330 cytoplasmic RNA Proteins 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- SHFKGANKURXVMY-LCWPZEQJSA-N hcv e2 protein Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)CC1=CC=CC=C1 SHFKGANKURXVMY-LCWPZEQJSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000001553 hepatotropic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009219 proapoptotic pathway Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012755 real-time RT-PCR analysis Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 230000007444 viral RNA synthesis Effects 0.000 description 1
- 230000007733 viral latency Effects 0.000 description 1
- 230000007419 viral reactivation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24251—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2436104 CA2436104A1 (fr) | 2003-07-14 | 2003-07-14 | Methode d'induction de la reproduction in vitro du virus de l'hepatite c (vhc), cellules et lignees cellulaires permettant la reproduction fidele du vhc et trousse connexe |
| CA 2454540 CA2454540A1 (fr) | 2003-07-14 | 2004-02-06 | Methode d'induction de la reproduction in vitro du virus de l'hepatite c (vhc), cellules et lignees cellulaires permettant la reproduction fidele du vhc et trousse connexe |
| PCT/CA2004/001009 WO2005005625A2 (fr) | 2003-07-14 | 2004-07-14 | Procede pour induire la replication du virus de l'hepatite c (hcv) in vitro, cellules et lignees cellulaires permettant une replication de hcv robuste et kit prevu a cet effet |
| US10/564,886 US20070099179A1 (en) | 2003-07-14 | 2004-07-14 | Method for inducing hepatitis c virus (hcv) replication in vitro, cells and cell lines enabling robust hcv replication and kit therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2436104 CA2436104A1 (fr) | 2003-07-14 | 2003-07-14 | Methode d'induction de la reproduction in vitro du virus de l'hepatite c (vhc), cellules et lignees cellulaires permettant la reproduction fidele du vhc et trousse connexe |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2436104A1 true CA2436104A1 (fr) | 2005-01-14 |
Family
ID=33569553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2436104 Abandoned CA2436104A1 (fr) | 2003-07-14 | 2003-07-14 | Methode d'induction de la reproduction in vitro du virus de l'hepatite c (vhc), cellules et lignees cellulaires permettant la reproduction fidele du vhc et trousse connexe |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2436104A1 (fr) |
-
2003
- 2003-07-14 CA CA 2436104 patent/CA2436104A1/fr not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kato | Molecular virology of hepatitis C virus | |
| Yoo et al. | Transfection of a differentiated human hepatoma cell line (Huh7) with in vitro-transcribed hepatitis C virus (HCV) RNA and establishment of a long-term culture persistently infected with HCV | |
| Chevaliez et al. | HCV genome and life cycle | |
| Pietschmann et al. | Persistent and transient replication of full-length hepatitis C virus genomes in cell culture | |
| Xiang et al. | Full-length GB virus C (Hepatitis G virus) RNA transcripts are infectious in primary CD4-positive T cells | |
| Ikeda et al. | Human hepatocyte clonal cell lines that support persistent replication of hepatitis C virus | |
| Post et al. | Immunological determinants of the outcomes from primary hepatitis C infection | |
| Kondo et al. | Hepatitis C virus infects T cells and affects interferon-γ signaling in T cell lines | |
| CN102016026A (zh) | 含有来自丙型肝炎病毒的嵌合基因的核酸 | |
| US20100159467A1 (en) | Method for replicating the hepatitis c virus | |
| Kato et al. | Systems to culture hepatitis C virus | |
| Valli et al. | Transmission in vitro of hepatitis C virus from persistently infected human B‐cells to hepatoma cells by cell‐to‐cell contact | |
| Wang | Scotomas in molecular virology and epidemiology of hepatitis C virus | |
| Shi et al. | Hepatitis C viral RNA: challenges and promises | |
| Yoshikura et al. | Replication of hepatitis C virus | |
| Germi et al. | Mosquito cells bind and replicate hepatitis C virus | |
| Isaguliants | Hepatitis C virus clearance: the enigma of failure despite an impeccable survival strategy | |
| Feitelson | Hepatitis C virus: from laboratory to clinic | |
| Valli et al. | Molecular and cellular determinants of cell‐to‐cell transmission of HCV in vitro | |
| Steffan et al. | Ultrastructural observations in hepatitis Cvirus-infected lymphoid cells | |
| CA2436104A1 (fr) | Methode d'induction de la reproduction in vitro du virus de l'hepatite c (vhc), cellules et lignees cellulaires permettant la reproduction fidele du vhc et trousse connexe | |
| US20060121448A1 (en) | Method for inducing complete hepatitis c virus (hcv) replication in vitro | |
| CA2454540A1 (fr) | Methode d'induction de la reproduction in vitro du virus de l'hepatite c (vhc), cellules et lignees cellulaires permettant la reproduction fidele du vhc et trousse connexe | |
| Zhu et al. | Interactions between helper T-cell epitopes of hepatitis C virus | |
| US20130101986A1 (en) | In Vitro Method for obtaining Intrahepatic Fibroblasts Infected with Hepatitis C Virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |